PRAK-03202: A triple antigen VLP vaccine candidate against SARS CoV-2

Abstract The rapid development of safe and effective vaccines against SARS CoV-2 is the need of the hour for the coronavirus outbreak. Here, we have developed PRAK-03202, the world’s first triple antigen VLP vaccine candidate in a highly characterized S. cerevisiae-based D-CryptTM platform, which in...

Full description

Saved in:
Bibliographic Details
Published in:bioRxiv 2020-10
Main Authors: Mazumder, Saumyabrata, Rastogi, Ruchir, Undale, Avinash, Arora, Kajal, Nupur Mehrotra Arora, Pratim, Biswa, Kumar, Dilip, Abyson, Joseph, Mali, Bhupesh, Arya, Vidya Bhushan, Kalyanaraman, Sriganesh, Mukherjee, Abhishek, Gupta, Aditi, Potdar, Swaroop, Sourav Singha Roy, Parashar, Deepak, Paliwal, Jeny, Singh, Sudhir Kumar, Naqvi, Aelia, Srivastava, Apoorva, Singh, Manglesh Kumar, Kumar, Devanand, Bansal, Sarthi, Rautray, Satabdi, Singh, Indrajeet, Fengade, Pankaj, Kumar, Bibekanand, Saini, Manish, Jain, Kshipra, Gupta, Reeshu, Kundu, Prabuddha Kumar
Format: Article
Language:English
Subjects:
Antigens
Coronaviruses
Epitopes
Immune response
Immune response (cell-mediated)
Immune response (humoral)
Immunization
Immunology
Lymphocytes T
Membrane proteins
Vaccines
γ-Interferon
Citations: Items that this one cites
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-b1045-2021586f9ca043f7de6455bc968f79807e2f486ab59a83f066e312439aaa14853
container_end_page
container_issue
container_start_page
container_title bioRxiv
container_volume
creator Mazumder, Saumyabrata
Rastogi, Ruchir
Undale, Avinash
Arora, Kajal
Nupur Mehrotra Arora
Pratim, Biswa
Kumar, Dilip
Abyson, Joseph
Mali, Bhupesh
Arya, Vidya Bhushan
Kalyanaraman, Sriganesh
Mukherjee, Abhishek
Gupta, Aditi
Potdar, Swaroop
Sourav Singha Roy
Parashar, Deepak
Paliwal, Jeny
Singh, Sudhir Kumar
Naqvi, Aelia
Srivastava, Apoorva
Singh, Manglesh Kumar
Kumar, Devanand
Bansal, Sarthi
Rautray, Satabdi
Singh, Indrajeet
Fengade, Pankaj
Kumar, Bibekanand
Saini, Manish
Jain, Kshipra
Gupta, Reeshu
Kundu, Prabuddha Kumar
description Abstract The rapid development of safe and effective vaccines against SARS CoV-2 is the need of the hour for the coronavirus outbreak. Here, we have developed PRAK-03202, the world’s first triple antigen VLP vaccine candidate in a highly characterized S. cerevisiae-based D-CryptTM platform, which induced SARS CoV-2 specific neutralizing antibodies in BALB/c mice. Immunizations using three different doses of PRAK-03202 induces antigen specific (Spike, envelope and membrane proteins) humoral response and neutralizing potential. PBMCs from convalescent patients, when exposed to PRAK-03202, showed lymphocyte proliferation and elevated IFN-γ levels suggestive of conservation of epitopes and induction of T helper 1 (Th1)–biased cellular immune responses. These data support the clinical development and testing of PRAK-03202 for use in humans. Competing Interest Statement The authors have declared no competing interest.
doi_str_mv 10.1101/2020.10.30.360115
format article
fullrecord <record><control><sourceid>proquest_COVID</sourceid><recordid>TN_cdi_proquest_journals_2507752205</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2507752205</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1045-2021586f9ca043f7de6455bc968f79807e2f486ab59a83f066e312439aaa14853</originalsourceid><addsrcrecordid>eNotUE1Lw0AUXATBUvsDvC148ZL69jO73kKoVgxYWu01vCSbsqUmMUmL_ntXKwy8BzPvY4aQGwZzxoDdc-Chg7kI0MCYuiATri2PDAd1RWbDsAcAbjUTsZyQxWqdvEQgwtgDTejY--7gKDaj37mGbrMVPWFZ-sbREpvKVzgGdoe-GUa6SdYbmrbbiF-TyxoPg5v91yl5f1y8pcsoe316TpMsKhhIFYUjTBld2xJBijqunJZKFaXVpo6tgdjxWhqNhbJoRA1aO8G4FBYRmTRKTMndeW_h2_7Ln_Ku9x_Yf-e_rnMGuQj4cx2kt2dp17efRzeM-b499k34LucK4ljxkIf4AUaWU4w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2507752205</pqid></control><display><type>article</type><title>PRAK-03202: A triple antigen VLP vaccine candidate against SARS CoV-2</title><source>Coronavirus Research Database</source><creator>Mazumder, Saumyabrata ; Rastogi, Ruchir ; Undale, Avinash ; Arora, Kajal ; Nupur Mehrotra Arora ; Pratim, Biswa ; Kumar, Dilip ; Abyson, Joseph ; Mali, Bhupesh ; Arya, Vidya Bhushan ; Kalyanaraman, Sriganesh ; Mukherjee, Abhishek ; Gupta, Aditi ; Potdar, Swaroop ; Sourav Singha Roy ; Parashar, Deepak ; Paliwal, Jeny ; Singh, Sudhir Kumar ; Naqvi, Aelia ; Srivastava, Apoorva ; Singh, Manglesh Kumar ; Kumar, Devanand ; Bansal, Sarthi ; Rautray, Satabdi ; Singh, Indrajeet ; Fengade, Pankaj ; Kumar, Bibekanand ; Saini, Manish ; Jain, Kshipra ; Gupta, Reeshu ; Kundu, Prabuddha Kumar</creator><creatorcontrib>Mazumder, Saumyabrata ; Rastogi, Ruchir ; Undale, Avinash ; Arora, Kajal ; Nupur Mehrotra Arora ; Pratim, Biswa ; Kumar, Dilip ; Abyson, Joseph ; Mali, Bhupesh ; Arya, Vidya Bhushan ; Kalyanaraman, Sriganesh ; Mukherjee, Abhishek ; Gupta, Aditi ; Potdar, Swaroop ; Sourav Singha Roy ; Parashar, Deepak ; Paliwal, Jeny ; Singh, Sudhir Kumar ; Naqvi, Aelia ; Srivastava, Apoorva ; Singh, Manglesh Kumar ; Kumar, Devanand ; Bansal, Sarthi ; Rautray, Satabdi ; Singh, Indrajeet ; Fengade, Pankaj ; Kumar, Bibekanand ; Saini, Manish ; Jain, Kshipra ; Gupta, Reeshu ; Kundu, Prabuddha Kumar</creatorcontrib><description>Abstract The rapid development of safe and effective vaccines against SARS CoV-2 is the need of the hour for the coronavirus outbreak. Here, we have developed PRAK-03202, the world’s first triple antigen VLP vaccine candidate in a highly characterized S. cerevisiae-based D-CryptTM platform, which induced SARS CoV-2 specific neutralizing antibodies in BALB/c mice. Immunizations using three different doses of PRAK-03202 induces antigen specific (Spike, envelope and membrane proteins) humoral response and neutralizing potential. PBMCs from convalescent patients, when exposed to PRAK-03202, showed lymphocyte proliferation and elevated IFN-γ levels suggestive of conservation of epitopes and induction of T helper 1 (Th1)–biased cellular immune responses. These data support the clinical development and testing of PRAK-03202 for use in humans. Competing Interest Statement The authors have declared no competing interest.</description><edition>1.1</edition><identifier>EISSN: 2692-8205</identifier><identifier>DOI: 10.1101/2020.10.30.360115</identifier><language>eng</language><publisher>Cold Spring Harbor: Cold Spring Harbor Laboratory Press</publisher><subject>Antigens ; Coronaviruses ; Epitopes ; Immune response ; Immune response (cell-mediated) ; Immune response (humoral) ; Immunization ; Immunology ; Lymphocytes T ; Membrane proteins ; Vaccines ; γ-Interferon</subject><ispartof>bioRxiv, 2020-10</ispartof><rights>2020. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (“the License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020, Posted by Cold Spring Harbor Laboratory</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-b1045-2021586f9ca043f7de6455bc968f79807e2f486ab59a83f066e312439aaa14853</cites><orcidid>0000-0002-9447-2812</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2507752205?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,780,784,885,27923,38514,43893</link.rule.ids><linktorsrc>$$Uhttps://www.proquest.com/docview/2507752205?pq-origsite=primo$$EView_record_in_ProQuest$$FView_record_in_$$GProQuest$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Mazumder, Saumyabrata</creatorcontrib><creatorcontrib>Rastogi, Ruchir</creatorcontrib><creatorcontrib>Undale, Avinash</creatorcontrib><creatorcontrib>Arora, Kajal</creatorcontrib><creatorcontrib>Nupur Mehrotra Arora</creatorcontrib><creatorcontrib>Pratim, Biswa</creatorcontrib><creatorcontrib>Kumar, Dilip</creatorcontrib><creatorcontrib>Abyson, Joseph</creatorcontrib><creatorcontrib>Mali, Bhupesh</creatorcontrib><creatorcontrib>Arya, Vidya Bhushan</creatorcontrib><creatorcontrib>Kalyanaraman, Sriganesh</creatorcontrib><creatorcontrib>Mukherjee, Abhishek</creatorcontrib><creatorcontrib>Gupta, Aditi</creatorcontrib><creatorcontrib>Potdar, Swaroop</creatorcontrib><creatorcontrib>Sourav Singha Roy</creatorcontrib><creatorcontrib>Parashar, Deepak</creatorcontrib><creatorcontrib>Paliwal, Jeny</creatorcontrib><creatorcontrib>Singh, Sudhir Kumar</creatorcontrib><creatorcontrib>Naqvi, Aelia</creatorcontrib><creatorcontrib>Srivastava, Apoorva</creatorcontrib><creatorcontrib>Singh, Manglesh Kumar</creatorcontrib><creatorcontrib>Kumar, Devanand</creatorcontrib><creatorcontrib>Bansal, Sarthi</creatorcontrib><creatorcontrib>Rautray, Satabdi</creatorcontrib><creatorcontrib>Singh, Indrajeet</creatorcontrib><creatorcontrib>Fengade, Pankaj</creatorcontrib><creatorcontrib>Kumar, Bibekanand</creatorcontrib><creatorcontrib>Saini, Manish</creatorcontrib><creatorcontrib>Jain, Kshipra</creatorcontrib><creatorcontrib>Gupta, Reeshu</creatorcontrib><creatorcontrib>Kundu, Prabuddha Kumar</creatorcontrib><title>PRAK-03202: A triple antigen VLP vaccine candidate against SARS CoV-2</title><title>bioRxiv</title><description>Abstract The rapid development of safe and effective vaccines against SARS CoV-2 is the need of the hour for the coronavirus outbreak. Here, we have developed PRAK-03202, the world’s first triple antigen VLP vaccine candidate in a highly characterized S. cerevisiae-based D-CryptTM platform, which induced SARS CoV-2 specific neutralizing antibodies in BALB/c mice. Immunizations using three different doses of PRAK-03202 induces antigen specific (Spike, envelope and membrane proteins) humoral response and neutralizing potential. PBMCs from convalescent patients, when exposed to PRAK-03202, showed lymphocyte proliferation and elevated IFN-γ levels suggestive of conservation of epitopes and induction of T helper 1 (Th1)–biased cellular immune responses. These data support the clinical development and testing of PRAK-03202 for use in humans. Competing Interest Statement The authors have declared no competing interest.</description><subject>Antigens</subject><subject>Coronaviruses</subject><subject>Epitopes</subject><subject>Immune response</subject><subject>Immune response (cell-mediated)</subject><subject>Immune response (humoral)</subject><subject>Immunization</subject><subject>Immunology</subject><subject>Lymphocytes T</subject><subject>Membrane proteins</subject><subject>Vaccines</subject><subject>γ-Interferon</subject><issn>2692-8205</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><recordid>eNotUE1Lw0AUXATBUvsDvC148ZL69jO73kKoVgxYWu01vCSbsqUmMUmL_ntXKwy8BzPvY4aQGwZzxoDdc-Chg7kI0MCYuiATri2PDAd1RWbDsAcAbjUTsZyQxWqdvEQgwtgDTejY--7gKDaj37mGbrMVPWFZ-sbREpvKVzgGdoe-GUa6SdYbmrbbiF-TyxoPg5v91yl5f1y8pcsoe316TpMsKhhIFYUjTBld2xJBijqunJZKFaXVpo6tgdjxWhqNhbJoRA1aO8G4FBYRmTRKTMndeW_h2_7Ln_Ku9x_Yf-e_rnMGuQj4cx2kt2dp17efRzeM-b499k34LucK4ljxkIf4AUaWU4w</recordid><startdate>20201030</startdate><enddate>20201030</enddate><creator>Mazumder, Saumyabrata</creator><creator>Rastogi, Ruchir</creator><creator>Undale, Avinash</creator><creator>Arora, Kajal</creator><creator>Nupur Mehrotra Arora</creator><creator>Pratim, Biswa</creator><creator>Kumar, Dilip</creator><creator>Abyson, Joseph</creator><creator>Mali, Bhupesh</creator><creator>Arya, Vidya Bhushan</creator><creator>Kalyanaraman, Sriganesh</creator><creator>Mukherjee, Abhishek</creator><creator>Gupta, Aditi</creator><creator>Potdar, Swaroop</creator><creator>Sourav Singha Roy</creator><creator>Parashar, Deepak</creator><creator>Paliwal, Jeny</creator><creator>Singh, Sudhir Kumar</creator><creator>Naqvi, Aelia</creator><creator>Srivastava, Apoorva</creator><creator>Singh, Manglesh Kumar</creator><creator>Kumar, Devanand</creator><creator>Bansal, Sarthi</creator><creator>Rautray, Satabdi</creator><creator>Singh, Indrajeet</creator><creator>Fengade, Pankaj</creator><creator>Kumar, Bibekanand</creator><creator>Saini, Manish</creator><creator>Jain, Kshipra</creator><creator>Gupta, Reeshu</creator><creator>Kundu, Prabuddha Kumar</creator><general>Cold Spring Harbor Laboratory Press</general><general>Cold Spring Harbor Laboratory</general><scope>8FE</scope><scope>8FH</scope><scope>AAFGM</scope><scope>AAMXL</scope><scope>ABOIG</scope><scope>ABUWG</scope><scope>ADZZV</scope><scope>AFKRA</scope><scope>AFLLJ</scope><scope>AFOLM</scope><scope>AGAJT</scope><scope>AQTIP</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQCXX</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>FX.</scope><orcidid>https://orcid.org/0000-0002-9447-2812</orcidid></search><sort><creationdate>20201030</creationdate><title>PRAK-03202: A triple antigen VLP vaccine candidate against SARS CoV-2</title><author>Mazumder, Saumyabrata ; Rastogi, Ruchir ; Undale, Avinash ; Arora, Kajal ; Nupur Mehrotra Arora ; Pratim, Biswa ; Kumar, Dilip ; Abyson, Joseph ; Mali, Bhupesh ; Arya, Vidya Bhushan ; Kalyanaraman, Sriganesh ; Mukherjee, Abhishek ; Gupta, Aditi ; Potdar, Swaroop ; Sourav Singha Roy ; Parashar, Deepak ; Paliwal, Jeny ; Singh, Sudhir Kumar ; Naqvi, Aelia ; Srivastava, Apoorva ; Singh, Manglesh Kumar ; Kumar, Devanand ; Bansal, Sarthi ; Rautray, Satabdi ; Singh, Indrajeet ; Fengade, Pankaj ; Kumar, Bibekanand ; Saini, Manish ; Jain, Kshipra ; Gupta, Reeshu ; Kundu, Prabuddha Kumar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1045-2021586f9ca043f7de6455bc968f79807e2f486ab59a83f066e312439aaa14853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antigens</topic><topic>Coronaviruses</topic><topic>Epitopes</topic><topic>Immune response</topic><topic>Immune response (cell-mediated)</topic><topic>Immune response (humoral)</topic><topic>Immunization</topic><topic>Immunology</topic><topic>Lymphocytes T</topic><topic>Membrane proteins</topic><topic>Vaccines</topic><topic>γ-Interferon</topic><toplevel>online_resources</toplevel><creatorcontrib>Mazumder, Saumyabrata</creatorcontrib><creatorcontrib>Rastogi, Ruchir</creatorcontrib><creatorcontrib>Undale, Avinash</creatorcontrib><creatorcontrib>Arora, Kajal</creatorcontrib><creatorcontrib>Nupur Mehrotra Arora</creatorcontrib><creatorcontrib>Pratim, Biswa</creatorcontrib><creatorcontrib>Kumar, Dilip</creatorcontrib><creatorcontrib>Abyson, Joseph</creatorcontrib><creatorcontrib>Mali, Bhupesh</creatorcontrib><creatorcontrib>Arya, Vidya Bhushan</creatorcontrib><creatorcontrib>Kalyanaraman, Sriganesh</creatorcontrib><creatorcontrib>Mukherjee, Abhishek</creatorcontrib><creatorcontrib>Gupta, Aditi</creatorcontrib><creatorcontrib>Potdar, Swaroop</creatorcontrib><creatorcontrib>Sourav Singha Roy</creatorcontrib><creatorcontrib>Parashar, Deepak</creatorcontrib><creatorcontrib>Paliwal, Jeny</creatorcontrib><creatorcontrib>Singh, Sudhir Kumar</creatorcontrib><creatorcontrib>Naqvi, Aelia</creatorcontrib><creatorcontrib>Srivastava, Apoorva</creatorcontrib><creatorcontrib>Singh, Manglesh Kumar</creatorcontrib><creatorcontrib>Kumar, Devanand</creatorcontrib><creatorcontrib>Bansal, Sarthi</creatorcontrib><creatorcontrib>Rautray, Satabdi</creatorcontrib><creatorcontrib>Singh, Indrajeet</creatorcontrib><creatorcontrib>Fengade, Pankaj</creatorcontrib><creatorcontrib>Kumar, Bibekanand</creatorcontrib><creatorcontrib>Saini, Manish</creatorcontrib><creatorcontrib>Jain, Kshipra</creatorcontrib><creatorcontrib>Gupta, Reeshu</creatorcontrib><creatorcontrib>Kundu, Prabuddha Kumar</creatorcontrib><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>Biological Sciences</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>bioRxiv</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Mazumder, Saumyabrata</au><au>Rastogi, Ruchir</au><au>Undale, Avinash</au><au>Arora, Kajal</au><au>Nupur Mehrotra Arora</au><au>Pratim, Biswa</au><au>Kumar, Dilip</au><au>Abyson, Joseph</au><au>Mali, Bhupesh</au><au>Arya, Vidya Bhushan</au><au>Kalyanaraman, Sriganesh</au><au>Mukherjee, Abhishek</au><au>Gupta, Aditi</au><au>Potdar, Swaroop</au><au>Sourav Singha Roy</au><au>Parashar, Deepak</au><au>Paliwal, Jeny</au><au>Singh, Sudhir Kumar</au><au>Naqvi, Aelia</au><au>Srivastava, Apoorva</au><au>Singh, Manglesh Kumar</au><au>Kumar, Devanand</au><au>Bansal, Sarthi</au><au>Rautray, Satabdi</au><au>Singh, Indrajeet</au><au>Fengade, Pankaj</au><au>Kumar, Bibekanand</au><au>Saini, Manish</au><au>Jain, Kshipra</au><au>Gupta, Reeshu</au><au>Kundu, Prabuddha Kumar</au><format>book</format><genre>document</genre><ristype>GEN</ristype><atitle>PRAK-03202: A triple antigen VLP vaccine candidate against SARS CoV-2</atitle><jtitle>bioRxiv</jtitle><date>2020-10-30</date><risdate>2020</risdate><eissn>2692-8205</eissn><abstract>Abstract The rapid development of safe and effective vaccines against SARS CoV-2 is the need of the hour for the coronavirus outbreak. Here, we have developed PRAK-03202, the world’s first triple antigen VLP vaccine candidate in a highly characterized S. cerevisiae-based D-CryptTM platform, which induced SARS CoV-2 specific neutralizing antibodies in BALB/c mice. Immunizations using three different doses of PRAK-03202 induces antigen specific (Spike, envelope and membrane proteins) humoral response and neutralizing potential. PBMCs from convalescent patients, when exposed to PRAK-03202, showed lymphocyte proliferation and elevated IFN-γ levels suggestive of conservation of epitopes and induction of T helper 1 (Th1)–biased cellular immune responses. These data support the clinical development and testing of PRAK-03202 for use in humans. Competing Interest Statement The authors have declared no competing interest.</abstract><cop>Cold Spring Harbor</cop><pub>Cold Spring Harbor Laboratory Press</pub><doi>10.1101/2020.10.30.360115</doi><tpages>17</tpages><edition>1.1</edition><orcidid>https://orcid.org/0000-0002-9447-2812</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier EISSN: 2692-8205
ispartof bioRxiv, 2020-10
issn 2692-8205
language eng
recordid cdi_proquest_journals_2507752205
source Coronavirus Research Database
subjects Antigens
Coronaviruses
Epitopes
Immune response
Immune response (cell-mediated)
Immune response (humoral)
Immunization
Immunology
Lymphocytes T
Membrane proteins
Vaccines
γ-Interferon
title PRAK-03202: A triple antigen VLP vaccine candidate against SARS CoV-2
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T10%3A42%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_COVID&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=document&rft.atitle=PRAK-03202:%20A%20triple%20antigen%20VLP%20vaccine%20candidate%20against%20SARS%20CoV-2&rft.jtitle=bioRxiv&rft.au=Mazumder,%20Saumyabrata&rft.date=2020-10-30&rft.eissn=2692-8205&rft_id=info:doi/10.1101/2020.10.30.360115&rft_dat=%3Cproquest_COVID%3E2507752205%3C/proquest_COVID%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b1045-2021586f9ca043f7de6455bc968f79807e2f486ab59a83f066e312439aaa14853%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2507752205&rft_id=info:pmid/&rfr_iscdi=true